Physician profile
Deepakta Kaur
NPI 1538620232
$1,677.21
in general payments reported to CMS, 2019-2025
21 companies · $52.38 in 2025
The $52.38 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $103 · 2023: $438 · 2024: $1,084 · 2025: $52.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,573.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $350.16 | 2022-2024 | |
| Novo Nordisk INC | $321.55 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $201.55 | 2023-2024 | Zepbound, Jardiance, Mounjaro |
| Amgen INC. | $166.99 | 2022-2025 | Repatha, Otezla, Evenity |
| Sumitomo Pharma America, INC. | $88.20 | 2024 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $85.42 | 2024 | Airsupra, Farxiga |
| Pfizer INC. | $60.85 | 2023-2024 | |
| Exact Sciences Corporation | $54.88 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.83 | 2024 | Jardiance |
| Astellas Pharma US INC | $41.22 | 2022-2023 | Veozah |
| Insulet Corporation | $37.65 | 2023-2024 | Omnipod |
| Dynavax Technologies Corporation | $37.25 | 2024 | Heplisav-B |
| Irhythm Technologies, INC. | $30.74 | 2024 | Zio Monitor, Zio Xt Patch |
| Boston Scientific Corporation | $29.10 | 2025 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $27.66 | 2024 | Capvaxive, Gardasil 9, Gardasil |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $19.60 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.63 | 2024 | |
| Currax Pharmaceuticals LLC | $16.97 | 2024 | Onzetra Xsail, Contrave |
| Glaxosmithkline, LLC. | $15.46 | 2024 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $14.32 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.18 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepakta Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.